Amlodipine And Atorvastatin Tablet, Film Coated
Product Images NDC 72162-2091

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Amlodipine And Atorvastatin (NDC 72162-2091). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Amlodipine Besylate And Atorvastatin Calcium 02)

A line graph displaying event rates over time (months) comparing Amlodipine and Placebo groups. The graph shows event rate on the Y-axis and time in months on the X-axis, with two labeled curves for Placebo and Amlodipine. The graph includes a statistical summary box with p-value, hazard ratio, and confidence interval.*

FDA Label Image

Figure 2 (Amlodipine Besylate And Atorvastatin Calcium 03)

A forest plot chart depicting hazard ratios with 95% confidence intervals comparing Amlodipine and placebo across various patient subgroups. Subgroups analyzed include overall patients, age (<65 and ≥65), gender (male and female), baseline sitting systolic blood pressure, baseline vessel disease (single and multiple), presence of vessels with stenosis, and PCI-stent strata. The x-axis represents hazard ratio values from 0.0 to 2.0, with a vertical line marking 1.0.*

FDA Label Image

Figure 3 (Amlodipine Besylate And Atorvastatin Calcium 04)

A line graph comparing the cumulative incidence percentage over time (years) between Atorvastatin and placebo groups in a clinical study. The graph shows lower incidence rates for Atorvastatin. Hazard ratio (HR) and p-value indicating statistical analysis results are included.*

FDA Label Image

Figure 4 (Amlodipine Besylate And Atorvastatin Calcium 05)

A cumulative hazard graph comparing the cumulative hazard percentage over time (in years) to the first primary endpoint through four years of follow-up. It shows two lines: one for Atorvastatin and one for Placebo, with Placebo having a higher cumulative hazard throughout the period. Hazard ratio and p-value are noted on the graph.*

FDA Label Image

Figure 5 (Amlodipine Besylate And Atorvastatin Calcium 06)

A line graph depicting the percentage of subjects experiencing the first major cardiovascular event over five years. Two lines compare Atorvastatin 10 mg (dashed line) and Atorvastatin 80 mg (solid line), showing a lower event rate with the higher dose. The graph includes a hazard ratio (HR) of 0.78 with confidence intervals and a p-value, indicating statistical analysis of the data.*

FDA Label Image

Amlodipine (Amlodipine)

Chemical structure diagrams of amlodipine and atorvastatin are shown, depicting their molecular arrangements with various characteristic chemical groups and bonds clearly illustrated.*

FDA Label Image

Atorvastatin-glycol-solvate (Atorvastatin Glycol Solvate)

Chemical structure of Amlodipine and Atorvastatin as indicated by the calcium salt form and associated molecular components shown in the image.*

FDA Label Image

Label (Lbl721622091)

Label for Amlodipine and Atorvastatin Tablets, USP with a strength of 10 mg/40 mg. The label states that each film-coated tablet contains amlodipine besylate equivalent to 10 mg amlodipine and atorvastatin calcium equivalent to 40 mg atorvastatin. The package contains 30 tablets. The product is relabeled by Bryant Ranch Prepack, Inc. and manufactured by Apotex Inc. Storage instructions and warnings about keeping medication out of reach of children and protecting from moisture are also included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.